Terbinex

Quick links to important sections

Terbinex

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbinex

What is Terbinex? Overview and Quick Facts

Property Description
Active ingredient Terbinafine Hydrochloride
Forms Tablets (oral), Cream, Spray, Solution (topical)
Pharmacological Class Allylamine Antifungal Agent
Origin Synthetic

Terbinex is the commercial designation for medication containing the active ingredient Terbinafine Hydrochloride, a synthetic therapeutic substance internationally classified as an antifungal agent. This compound belongs specifically to the allylamine pharmacological class, a group recognized for its activity against dermatophyte organisms.

The medication's primary component, Terbinafine Hydrochloride, is formulated into several distinct dosage forms tailored to address therapeutic requirements. These include oral tablets intended for systemic absorption into the body, and various topical preparations (cream, spray, or solution) for application directly to the skin. The offering of both systemic and topical formulations is a differentiating factor, intended to address both superficial skin conditions and issues affecting the nails, where systemic delivery is often necessary.

The mechanism of Terbinafine involves the inhibition of squalene epoxidase, establishing the process that leads to the disruption of fungal cell membranes. This mechanism defines the medication's overall purpose: to provide clearance of the fungal organisms responsible for the ailment. Terbinex, therefore, is positioned as a solution within the antifungal landscape, offering versatility in form to suit varied patient presentations.

Regulatory References

  1. Terbinafine Public Assessment Report (MEB/CBG)

What side effects are possible with Terbinex?

Possible side effects and safety information

The safety profile of Terbinex (Terbinafine) is defined by official regulatory classifications that group adverse reactions by frequency and affected body system. Adverse reactions are grouped by System-Organ Class (SOC), with common effects primarily involving the Gastrointestinal and Nervous Systems.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards based on their frequency of reporting in clinical documents:

  • Very Common (ge 1/10): Commonly reported effects include headache, various gastrointestinal disturbances (such as nausea, diarrhea, abdominal pain, and dyspepsia), skin rash, urticaria, arthralgia, and myalgia.
  • Common (ge 1/100 to < 1/10): Includes dysgeusia (taste disturbance) which may lead to ageusia (loss of taste), dizziness, and fatigue.

Serious Adverse Reactions and Safety Limitations

Regulatory documents list rare but clinically significant adverse reactions. These include reports of hepatotoxicity and liver failure, which have occasionally resulted in the need for a liver transplant or death. Severe, potentially life-threatening dermatologic reactions are also documented, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Specific limitations exist for certain populations. The oral formulation is not recommended for patients with pre-existing chronic or active liver disease or significant renal impairment. Furthermore, the substance is excreted in breast milk, and mothers should not breast-feed while taking the oral form. Taste disturbance, including taste loss, may be prolonged or, in rare cases, permanent, although resolution typically occurs within weeks after discontinuation.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Officially documented cases of acute oral overdose, involving exposure up to 5 grams of the active substance, typically present with symptoms affecting the gastrointestinal tract and the central nervous system. Documented clinical manifestations include nausea, vomiting, epigastric pain, headache, and dizziness. Less common manifestations such as rash and increased urination have also been reported in official summaries. Overdose is considered extremely unlikely following topical application due to minimal systemic absorption, although accidental large ingestion of the topical form is expected to cause effects similar to oral overdose.

When Immediate Medical Help is Required

Patients must seek emergency medical attention immediately, or contact a Poison Help line if an overdose is suspected. This immediate action is mandated because no specific antidote is known for the active substance, meaning management relies entirely on procedural support. Urgent medical help is also required if the patient exhibits signs indicative of severe outcomes, such as symptoms of potential liver injury (e.g., jaundice, persistent nausea, or dark urine). In these cases, the immediate evaluation of hepatic function is a required action.

Official Management Protocol

The regulated management protocol focuses on symptomatic supportive therapy and procedural steps to eliminate the active substance from the body. This typically involves the administration of activated charcoal. Furthermore, the product must be discontinued immediately if the patient develops clinical or laboratory signs of severe adverse reactions, including liver injury or a progressive severe skin rash, as stated in regulatory documents.

Therapeutic Uses of Terbinex

What Terbinex Treats: Main Uses and Benefits

Terbinex is commonly used across conditions presenting with systemic or localized discomfort, such as those established in the nail matrix (onychomycosis) or the scalp (Tinea Capitis). In clinical practice, the medication is utilized in settings that involve deep-seated fungal infections where systemic management is required.

The medication is also relevant for managing symptom clusters that may become intense or disruptive in conditions presenting with recurrent manifestations of fungal skin infections, including ringworm of the body (Tinea Corporis), jock itch (Tinea Cruris), and severe forms of athlete’s foot (Tinea Pedis), alongside other cutaneous mycoses like Pityriasis Versicolor.

The medication is applied in situations where symptoms interfere with daily functioning, such as persistent scaling, intense itching (pruritus), and widespread redness (erythema). Addressing the core symptomatic issue can contribute to easing the overall symptom burden, which supports day-to-day comfort and stability.

Quick Fact: Relevant for symptoms related to inflammatory or irritative states.

“The medication is applied to support the reduction of symptoms related to inflammatory or irritative states, which assists with maintaining functional stability.”

Eligibility and Restrictions for Use

Terbinex (terbinafine) tablets are prescribed to treat specific fungal infections, particularly those affecting the nails (onychomycosis) and skin (tinea infections) that have not responded to topical treatment.

Contraindications (Who cannot use Terbinex?)

Terbinex is not suitable for all patients. It should not be used by individuals with:

  • A known allergy or hypersensitivity to terbinafine or any other component of the tablet.
  • Existing chronic or active liver disease, due to the risk of serious liver injury, which in rare cases can lead to liver transplant or death. Liver function tests are often performed before and during treatment.

Precautions (Discuss with your doctor)

Consult your healthcare provider before starting Terbinex if you have or plan to:

Patient Group / Condition Key Consideration
Pre-existing Kidney Issues Dose adjustments or careful monitoring may be necessary.
Lupus (Systemic Lupus Erythematosus) Terbinex may potentially worsen the condition.
Pregnancy or Breastfeeding Use is generally avoided as the drug can pass into breast milk and data on safety during pregnancy is limited.

It is also essential to inform your doctor about all other medications, supplements, and herbal products you are taking, as Terbinex can interact with many drugs, including certain antidepressants, heart medications (e.g., beta-blockers), and rifampin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Terbinex (terbinafine) can interact with a number of medicines by affecting the way they are metabolized, primarily due to its documented effect as an inhibitor of the CYP450 2D6 (CYP2D6) enzyme. This interaction profile is strictly defined in official regulatory labeling.

Documented Pharmacokinetic Interactions

The most clinically relevant interaction involves medicines that are primarily metabolized by the CYP2D6 enzyme. Co-administration of Terbinex with these substrates can significantly increase their concentration in the body. Affected categories include:

  • Antidepressants: Tricyclic antidepressants (e.g., desipramine, nortriptyline) and Selective Serotonin Reuptake Inhibitors (SSRIs).
  • Antiarrhythmics: Certain Class 1C agents (e.g., flecainide, propafenone).
  • Beta-blockers: (e.g., metoprolol, carvedilol).
  • Opioids: Certain opioid analgesics (e.g., codeine, tramadol).

Regulatory documents emphasize that the co-administration of Terbinex with these medicines requires careful patient monitoring and may necessitate a reduction in the dose of the co-administered drug.

Restrictions and Other Constraints

Official labeling contains specific constraints:

  • Not Recommended: Co-administration with pimozide and ranolazine is not recommended.
  • Avoid Concurrent Use: Avoid concurrent use with tamoxifen due to the potential for reduced efficacy of the active metabolites.
  • Enzyme Inducers/Inhibitors: Medicines that inhibit (e.g., cimetidine, fluconazole) or induce (e.g., rifampin) CYP enzymes can increase or decrease the concentration of Terbinex, respectively. The use of warfarin requires monitoring for changes in INR/prothrombin time.

Mechanism of Action

Targeted Blockade of Fungal Sterol Synthesis

Terbinex primarily functions by acting as a non-competitive inhibitor of the enzyme Squalene Epoxidase (SQLE), a critical molecular target in the fungal cell's Ergosterol Biosynthesis Pathway. This targeted enzyme blockade initiates a toxic biochemical cascade, which is the foundation of the drug's cellular effect.


Dual Mechanism for Fungal Cell Disruption

The enzymatic blockade results in a dual destructive effect on the fungal organism. It causes a profound depletion of Ergosterol, compromising the structural integrity of the cell membrane, while simultaneously leading to the toxic accumulation of Squalene inside the cell. The combination of structural failure and biochemical toxicity results in the physical lysis and death of the fungal cell.


Selectivity and Mechanistic Constraints

The drug's mechanism exhibits high selectivity for the fungal SQLE enzyme, reducing affinity for the mammalian cholesterol synthesis pathway. However, this focused mechanism is subject to constraint by the organism's ability to develop SQLE gene mutations, which can structurally alter the enzyme, reducing the binding affinity of Terbinafine and diminishing its physiological action.

Dosage and Administration Information

How to Use Terbinex: General Administration Guidelines

Terbinex (Terbinafine) is administered through distinct routes depending on the type of application required.

Administration Scope

Feature Instructional Summary
Route of Administration Administered orally (Tablets or Granules) for systemic use or topically (Cream, Spray, Solution) for localized dermatologic application.
Dosing Schedule (Adults) The standard regimen for oral tablets is 250 mg once daily.
Timing in Relation to Meals Oral Tablets may be taken with or without food. Oral Granules are intended to be mixed with non-acidic soft food and taken once a day with food; they are not mixed with fruit-based foods.
Preparation Requirements Oral tablets are swallowed whole. Oral granules are swallowed immediately after mixing and must not be chewed.
Course Duration Rules Oral treatment involves fixed, time-bound courses: typically 6 weeks for fingernail onychomycosis and 12 weeks for toenail onychomycosis.

Use Protocol and Population Rules

The use of oral Terbinex typically involves a once-daily regimen for systemic therapy, while topical applications may involve once or twice daily use. The oral form is not recommended for individuals with active liver disease or significant renal impairment, defined as a creatinine clearance of 50 mL/min or less. Pediatric application for oral granules is weight-based for certain indications, following a defined 6-week course. If an oral dose is missed, the regular schedule is resumed without taking two doses together.

Standard protocols follow a structured use based on fixed durations and a non-titrated dose, maintaining consistency between the administration route and the required therapeutic approach.

Recent Clinical Evidence

Terbinex: Recent Clinical Evidence

Summary of Clinical Trials

Research has investigated the use of Terbinex (terbinafine) for treating specific types of fungal infections, primarily those caused by dermatophytes, such as onychomycosis (nail fungus). Studies typically follow a randomized, placebo-controlled design to compare outcomes between participants receiving the compound and those receiving an inactive substance.

Efficacy Findings

Clinical trials have focused on measuring changes in infection clearance and symptom presentation in adult participants.

  • Toenail Onychomycosis: One randomized study examining oral terbinafine over periods of 6 to 24 weeks noted that cure rates were higher in participants receiving the compound compared to a placebo. The findings indicated a dose-duration relationship, with a 12-week course often used to assess long-term clearance.
  • Skin Infections: Studies evaluating topical terbinafine for skin infections (such as tinea pedis and tinea cruris) demonstrated that positive outcomes, measured by clinical and mycological clearance, were statistically distinct from the vehicle (placebo) beginning within the first few weeks of application.

Safety and Side Effect Profile

Research evaluated the frequency and type of adverse events reported by participants during trials.

  • Common Events: The most frequently reported adverse events across studies generally involve the gastrointestinal system and skin. These findings often include headache, diarrhea, rash, and upset stomach. Reports often categorized these symptoms as mild and temporary.
  • Taste/Smell Changes: Alterations in the sense of taste or smell have been reported. In some cases, these changes were severe enough to potentially affect appetite.
  • Liver Function: Studies documented rare but serious adverse events related to liver function, including elevated liver enzymes. Due to this observation, monitoring of liver function is sometimes suggested when using oral forms of the medication.

Key Studies & References

  1. Terbinafine - LiverTox - NCBI Bookshelf (Safety/Hepatotoxicity)

Frequently Asked Questions (FAQ)

Common questions about Terbinex (FAQ)


Q: How quickly should I expect to see results after starting Terbinex?

Studies and official information indicate that for skin infections, positive clinical outcomes have been reported within the first few weeks of application. For nail infections, the treatment is a fixed course of several weeks or months. Full clearance can take time due to the slow growth rate of the nails, meaning the final results are assessed long after the medication course is finished.

Q: What is the typical prescribed duration for Terbinex treatment?

According to the official product information, oral Terbinex is prescribed for fixed, time-bound treatment courses, which are typically 6 or 12 weeks for nail infections. The duration of therapy is strictly determined by the specific condition being treated, as established during clinical trials.

Q: Can people with liver issues use Terbinex, and what precautions are necessary?

Official information states that oral Terbinex is contraindicated, meaning it should not be used by individuals with chronic or active liver disease. Due to the risk of liver toxicity, liver function monitoring, often through blood tests, is a common precaution outlined in regulatory guidelines.

Q: Are there any specific monitoring tests required when taking Terbinex (e.g., blood tests)?

Monitoring of liver function, typically using blood tests, is outlined as a frequent precaution in official product information. This is usually performed before starting and periodically during treatment with oral Terbinex.

Q: Can I crush or split my Terbinex tablet if I have trouble swallowing pills?

Regulatory instructions clearly state that oral tablets should be swallowed whole. If the oral granule form is prescribed, instructions specify that it must be mixed with non-acidic soft food and swallowed without chewing.

Q: What happens if you stop taking Terbinex suddenly?

The full prescribed course is necessary to effectively treat the infection. The regulatory information addresses missed doses by advising resumption of the regular schedule. Changes to the treatment schedule must be reviewed by a healthcare provider.

Q: Can I take Terbinex with my daily multivitamin?

Regulatory documents detail interactions with prescription medicines that affect certain liver enzymes (CYP2D6 inhibitors). Standard multivitamin supplements are not specifically documented to interact negatively with Terbinex in the official label.

Q: Can women who are planning to become pregnant take Terbinex?

Use of Terbinex during an established pregnancy is generally avoided. A healthcare provider should be consulted before starting treatment in this situation, as safety data regarding use during the pre-conception or planning stage is limited.

Q: Is Terbinex suitable for people who have kidney disease?

Oral Terbinex is generally not recommended for patients with significant renal impairment, defined as having a creatinine clearance of 50 mL/min or less. If a person has pre-existing kidney issues, regulatory guidelines recommend caution and often suggest careful monitoring or dose adjustments.

Q: Does Terbinex affect cholesterol levels?

The mechanism of action of Terbinex is designed to target a specific enzyme in the fungal cell pathway, which differs from the pathway responsible for making cholesterol in humans. Regulatory adverse event documentation does not report systemic cholesterol changes as a noted side effect.

Q: Do older adults need a different dosage or monitoring when taking Terbinex?

The standard adult dosage is typically used for older adults. However, official information advises caution in this population. Prescribing physicians may use caution due to the greater likelihood of decreased liver, kidney, or heart function, or the use of other medications that may interact.

Q: What is the difference between Terbinex tablets and other forms (if applicable)?

Terbinex is available as oral tablets for systemic treatment, which means the medicine is absorbed throughout the body, typically for nail infections. Topical forms like cream, spray, or solution are applied directly to the skin for localized infections.

Q: Is Terbinex a steroid?

No, Terbinex is not a steroid. It belongs to a specific group of medications called allylamine antifungal agents.

Q: Can Terbinex cause weight gain?

Weight gain is not listed as one of the common or frequently reported adverse reactions in the official regulatory documents.

Q: Is it normal to feel a bit tired when you first start taking Terbinex?

Fatigue, or feeling tired, is listed in the official documents as a common adverse reaction, meaning it is reported in ge 1/100 to < 1/10 patients.

Q: Does Terbinex affect sleep patterns?

Sleep disturbance or insomnia is not listed as a common or specific adverse reaction in the regulatory documents for Terbinex.

Q: Are there any common foods or drinks that interact negatively with Terbinex?

When taking the oral tablets, the official guidance states you may take them with or without food. However, the oral granules must be mixed with non-acidic soft food and should not be mixed with fruit-based foods. No specific negative interactions with common drinks are documented.

Q: Is Terbinex a controlled substance or addictive in any way?

Terbinex is not classified as a controlled substance by the Drug Enforcement Administration (DEA) and is not known to be addictive.

Q: Is there a generic version of Terbinex available yet?

The active ingredient in Terbinex, terbinafine hydrochloride, is widely available in generic formulations.

Q: Can people with high blood pressure safely use Terbinex?

High blood pressure is not listed as a contraindication for Terbinex. However, Terbinex can interact with certain types of heart medications, such as beta-blockers. For this reason, monitoring may be necessary if you are taking medication for high blood pressure.

Q: Will Terbinex show up on a standard drug test?

Terbinex is an antifungal medication and is not classified as a controlled substance. Information regarding its detection in standard drug screens is not included in the official regulatory documents.

Q: Is it okay to drink alcohol in moderation while taking Terbinex?

Regulatory documents do not explicitly prohibit alcohol use. However, because Terbinex carries a risk of rare but serious liver adverse events, any decision regarding alcohol consumption while taking this medication should be reviewed by a healthcare provider.

Q: Can Terbinex be taken long-term for a chronic condition?

Oral Terbinex is typically prescribed for fixed, short-term courses, such as 6 or 12 weeks, as established in clinical trials. It is not generally intended for indefinite long-term use.

Q: Does Terbinex cause dry mouth or dry eyes?

Dry mouth or dry eyes are not listed as common or frequently reported adverse reactions in the official regulatory documents.

Q: Can Terbinex cause changes in mood or anxiety levels?

Psychiatric adverse reactions are not listed as common side effects. However, rare cases of mood changes, including depression and anxiety-related symptoms, have been reported in post-marketing experience.

Q: Why do some people say Terbinex stopped working for them after a few months?

Official information indicates that the drug's mechanism can be constrained by the fungal organism's ability to mutate a specific enzyme called SQLE. These changes can reduce the binding of Terbinex, which may diminish its effectiveness over time.

Q: Are there any skin reactions or rashes associated with Terbinex?

Yes, skin rash and hives (urticaria) are listed as very common adverse reactions. Furthermore, rare but serious skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been documented.

Q: Can teenagers or children take Terbinex?

The oral granule formulation has FDA approval for use in pediatric patients with certain fungal infections. Dosage for children and teenagers is typically weight-based and is prescribed for a defined course duration.

Q: Why is Terbinex a prescription-only medication?

Terbinex is restricted to prescription use because the oral formulation requires medical oversight. This is primarily due to the need for monitoring, such as checking liver function, to manage the drug’s known risks.

Q: Does sunlight exposure pose a risk while taking Terbinex?

Photosensitivity, or an increased sensitivity to sunlight, is not listed as a common or specific adverse reaction in the official regulatory documents.

Q: Are there any known genetic factors that affect how Terbinex works for someone?

Terbinex is known to inhibit the CYP2D6 enzyme, which is involved in metabolizing many other drugs. Although the label details drug interactions related to this enzyme, it does not provide explicit information on how a patient's own genetic variations in CYP2D6 status affect the drug’s effectiveness for them.

Q: What should I do if I miss a dose of Terbinex?

If you miss an oral dose, the regulatory instruction is to resume your regular schedule. Taking two doses at the same time to compensate for a missed dose is not recommended.

Q: Is there a specific time of day that is best to take Terbinex?

The official regimen for the oral tablets is once daily. The regulatory label does not specify a particular time of day as optimal for dosing, and the lack of specific instruction indicates that the exact time of day for dosing is generally flexible.

Q: Are there any natural supplements that should be avoided while on Terbinex?

Official information details interactions with medicines that are known to inhibit or induce certain CYP enzymes. It is important for a healthcare provider to review any supplements or medications that affect these enzymes to prevent potential changes in drug concentration.

Q: What is the success rate of Terbinex in clinical trials?

Clinical trials reported that participants receiving Terbinex achieved higher mycological cure rates compared to those receiving a placebo. Specific percentage success rates are detailed in the full clinical study reports.

Q: Is it possible to develop a tolerance to the effects of Terbinex over time?

Official information suggests that the targeted fungus can potentially develop genetic changes (mutations) in the SQLE enzyme. These changes can reduce the binding of Terbinex, which may diminish its effectiveness over time.

How should Terbinex be stored and disposed of?

How to Store and Dispose of Terbinafine Tablets

The official instructions for Terbinafine tablets require storage at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be kept in its original, tightly closed container and protected from light, excess moisture, heat, and freezing. This adherence is necessary to maintain the product's stability.

Mandatory Protection Requirements

Condition Requirement
Temperature Store between 20 C and 25 C.
Environment Protect from light, moisture, and freezing.
Safety Keep out of the sight and reach of children.

Disposal of unused or expired product must follow local regulations for pharmaceutical waste. Authorities often recommend utilizing a drug take-back program. If a take-back program is unavailable, the product may be mixed with an undesirable substance and placed in a sealed bag before being disposed of in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbinex found in:

A-Z Index: